<DOC>
	<DOCNO>NCT02105350</DOCNO>
	<brief_summary>This phase I study ( early study check safety new drug drug combination ) find safe tolerate dose combination oxaliplatin gemcitabine MEK 162 patient biliary cancer ( include gallbladder cancer cancer associate bile duct lead gallbladder liver ) curable surgery and/or spread beyond biliary tree ( place cancer start ) . Everyone receive standard dose oxaliplatin gemcitabine may receive different dos MEK 162 . MEK 162 new drug play important role regulation cell growth show shrink tumour patient biliary cancer type human cancer . This type drug also show shrink tumour give combination cisplatin gemcitabine research study do animal patient biliary cancer .</brief_summary>
	<brief_title>A Study MEK162 With Gemcitabine Oxaliplatin Biliary Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histopathological cytological diagnosis nonresectable , recurrent metastatic biliary tract ( intra extrahepatic ) gallbladder carcinoma . Have measurable disease . Not receive prior systemic therapy advance biliary cancer . Age 18 year age old . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Estimated life expectancy great 3 month . Have adequate hematological function . Have adequate cardiac function . All radiology study perform within 4 week prior start therapy . No evidence active uncontrolled infection . Ability understand willing sign write informed consent document . Ongoing prior toxicity relate previous treatment receive grade 1 less time registration . Able take oral medication . Progressing within 6 month receive adjuvant treatment biliary tract cancer . Not receive prior chemotherapy nonresectable metastatic disease MEK inhibitor . Histopathological cytological diagnosis ampullary carcinoma . Incomplete recovery previous surgery . Undergoing current treatment curative intent . History prior malignancy could interfere response evaluation . Any evidence severe uncontrolled systemic disease laboratory finding may affect participation trial . Any psychiatric disorder likely impact inform consent . Pregnant nursing ( lactate ) woman . Agree use highly effective method contraception throughout study 6 month study drug discontinuation . Significant cardiac disease . History retinal degenerative disease . History Gilbert 's syndrome . Known positive serology HIV , active hepatitis B , and/or active hepatitis C infection . Neuromuscular disorder associate elevated creatine kinase . Planning embark new strenuous exercise regimen first dose study treatment . Impairment gastrointestinal function gastrointestinal disease . Any condition would contraindicate participation clinical study due safety concern compliance clinical study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>MEK162</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Non-resectable</keyword>
	<keyword>Recurrent metastatic</keyword>
</DOC>